NASHVILLE, Tenn. / Nov 20, 2023 / Business Wire / Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the following two upcoming conferences:
BTIG 3rd Annual Ophthalmology Day
Format: Fireside Chat (Virtual)
Date/Time: Monday, November 27, 2023, at 1:30 p.m. ET
Piper Sandler 35th Annual Healthcare Conference (The Lotte New York Palace, New York, NY)
Format: Fireside Chat (In-Person)
Date/Time: Thursday, November 30, 2023, at 8:00 a.m. ET
Harrow management will be available for one-on-one meetings during both conferences. Investors interested in meeting with management should contact their BTIG or Piper Sandler representative to request a meeting.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. For more information about Harrow, please visit harrow.com.
| Last Trade: | US$34.37 |
| Daily Change: | -1.25 -3.51 |
| Daily Volume: | 1,007,186 |
| Market Cap: | US$1.260B |
May 14, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
